Literature DB >> 28213009

Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.

Tomoyuki Hida1, Makoto Hamasaki2, Shinji Matsumoto2, Ayuko Sato3, Tohru Tsujimura3, Kunimitsu Kawahara4, Akinori Iwasaki5, Tatsuro Okamoto6, Yoshinao Oda7, Hiroshi Honda8, Kazuki Nabeshima9.   

Abstract

OBJECTIVES: Differentiating malignant pleural mesothelioma (MPM) from reactive mesothelial hyperplasia (RMH) is still challenging. Detection of homozygous deletion (HD) of 9p21 region including p16INK4A (p16) by fluorescence in situ hybridization (FISH) and immunohistochemical detection of loss of BRCA1 associated protein 1 (BAP1), are reliable markers for MPM diagnosis. However, not all laboratories are equipped to perform 9p21 FISH; immunohistochemistry (IHC) is a more common and feasible technique. Thus, we sought to develop a IHC-based method that could predict the deletion of p16 in MPM in concordance with 9p21 FISH.
MATERIALS AND METHODS: We examined the expression of the 9p21.3-related proteins (p14, p15, p16, and methylthioadenosine phosphorylase (MTAP)) and BAP1 using IHC in 51 MPM and 25 RMH cases, and assessed their correlation with HD of p16 detected by FISH. The diagnostic usefulness of IHC of the 9p21.3-related proteins and BAP1 and their combinations was assessed using the cut-off values set by receiver operating characteristic (ROC) analysis.
RESULTS: Among the 9p21.3-related proteins, MTAP IHC findings showed best concordance with 9p21 FISH results (kappa coefficient of 0.69) and a specificity of 100%. We also examined the combinations of MTAP IHC with the other products. The loss of p16 and MTAP had better concordance (kappa coefficient of 0.71), although lower specificity (85%). For differentiating MPM from RMH, only MTAP showed 100% specificity among the 9p21.3-related proteins, as did BAP1 IHC and 9p21 FISH. Among BAP1 combinations, only that of BAP1 with MTAP showed 100% specificity. Its sensitivity was 76.5%, which was lower than BAP1 IHC and 9p21 FISH combination (84.3%), but higher than BAP1 IHC alone (60.8%) or 9p21 FISH alone (60.8%).
CONCLUSIONS: A combination of MTAP or BAP1 loss detected by IHC can likely detect MPM with good sensitivity and 100% specificity, and serve as useful ancillary IHC for discriminating MPM from RMH. Copyright Â
© 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  9p21 FISH; BAP1; Diagnosis; Immunohistochemistry; MTAP; Malignant pleural mesothelioma

Mesh:

Substances:

Year:  2016        PMID: 28213009     DOI: 10.1016/j.lungcan.2016.12.017

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  25 in total

1.  Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.

Authors:  Yoshiaki Kinoshita; Makoto Hamasaki; Masayo Yoshimura; Shinji Matsumoto; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

2.  MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.

Authors:  David B Chapel; Jefree J Schulte; Kyra Berg; Andrew Churg; Sanja Dacic; Carrie Fitzpatrick; Francoise Galateau-Salle; Kenzo Hiroshima; Thomas Krausz; Nolwenn Le Stang; Stephanie McGregor; Kazuki Nabeshima; Aliya N Husain
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

3.  Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.

Authors:  Kaishi Satomi; Makoto Ohno; Yuko Matsushita; Masamichi Takahashi; Yasuji Miyakita; Yoshitaka Narita; Koichi Ichimura; Akihiko Yoshida
Journal:  Mod Pathol       Date:  2020-10-19       Impact factor: 7.842

Review 4.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

Review 5.  Pleural mesothelioma classification update.

Authors:  Mary Beth Beasley; Francoise Galateau-Salle; Sanja Dacic
Journal:  Virchows Arch       Date:  2021-01-21       Impact factor: 4.064

6.  5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.

Authors:  Ziyad Alsugair; Vahan Kepenekian; Tanguy Fenouil; Olivier Glehen; Laurent Villeneuve; Sylvie Isaac; Juliette Hommell-Fontaine; Nazim Benzerdjeb
Journal:  Virchows Arch       Date:  2022-05-16       Impact factor: 4.064

Review 7.  Pleural mesothelioma classification-update and challenges.

Authors:  Sanja Dacic
Journal:  Mod Pathol       Date:  2021-08-31       Impact factor: 7.842

8.  Malignant mesothelioma in situ: morphologic features and clinical outcome.

Authors:  Andrew Churg; Francoise Galateau-Salle; Anja C Roden; Richard Attanoos; Jan H von der Thusen; Ming-Sound Tsao; Nina Chang; Marc De Perrot; Sanja Dacic
Journal:  Mod Pathol       Date:  2019-08-02       Impact factor: 7.842

Review 9.  Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections.

Authors:  Maisa Yoshimoto; Olga Ludkovski; Jennifer Good; Ciro Pereira; Robert J Gooding; Jean McGowan-Jordan; Alexander Boag; Andrew Evans; Ming-Sound Tsao; Paulo Nuin; Jeremy A Squire
Journal:  Lab Invest       Date:  2018-01-16       Impact factor: 5.662

Review 10.  When the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines.

Authors:  Giulio Rossi; Fabio Davoli; Venerino Poletti; Alberto Cavazza; Filippo Lococo
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.